Exploring the role of generalized health biomarkers in Traumatic Brain Injury: A UK Biobank Study

Authors: Shubhi Sharma[1], Donald M. Lyall[1]

Institutions

[1]School of Health and Wellbeing, University of Glasgow

Text word count: 2,143

Abstract word count: 229

Tables: 0

Figures: 2

Supplementary Tables: 5

Supplementary Figures: 2

References: 40

List of Tables and Figures

Table 1: Generalized health biomarkers included in the UK Biobank inventory

Table 2: Chronic neurological conditions

Table 3: Covariate Summary

Table 4: Frequency by Assessment Centre (in %)

Table 5: Summary of Significant Biomarkers

Figure 1: Line plot of standardized betas for narrow-band TBI

Figure 2: Line plot of standardized betas for broad-band TBI

Figure 3: Heatmap of P-values for narrow-band TBI

Figure 4: Heatmap of P-values for broad-band TBI

Abstract

Background: The role of generalized health biomarkers remains widely unexplored in relation to TBI. However, they show association with worsened brain health and nervous system functioning. It is useful to explore potential relationship between TBI and generalized, circulating health biomarkers as surrogate endpoints that can be linked to severity and mortality.

Aim: This is a hypothesis-free study that investigates the potential relationship(s) between traumatic brain injury and 34 generalized, circulating health biomarkers using data collected by the UK Biobank.

Methods: Data from 419,778 white British participants are analyzed against 34 biomarkers from the UK Biobank database. TBI diagnosis is captured through ICD-10 codes and categorized as narrow-band and broad-band TBI. Multivariate linear regression analysis is conducted for changes in biomarkers in participants with TBI history vs. those with no history. This is analyzed across 4 models with increasing number of covariates and stratified for both categories of TBI.

Results: IGF-1, gamma glutamyltransferase and aspartase aminotransferase had significant results across all models in broad-band and narrow-band TBI ($P < 0.05$). An additional ten biomarkers showed statistically significant results in all models except the fully adjusted models.

Conclusion: IGF-1, GGT, and AST emerged as consistent indicators of systemic changes following TBI, highlighting their potential as surrogate markers for monitoring long-term outcomes. These findings suggest that incorporating generalized health biomarkers into clinical and research frameworks may improve early detection, risk stratification, and intervention strategies in TBI populations.

Author contributions

Study concept: DML, SS.

Obtained data: UK Biobank.

Design: DML, SS.

Conducted analyses: SS, DML.

Drafted original manuscript: SS.

Reviewed for intellectual content: DML, SS.

Introduction

TBI is the leading cause for deaths and disabilities in adults under the age of 45 years, with over 69 million cases worldwide[1]. Despite its burden, TBI remains a poorly understood condition[2]. This is attributed to the condition's heterogeneity, due its definition and severity remaining highly variable, and its impact on a wide range of granular physiological factors, as evidenced by patients with similar injuries experiencing distinct recovery trajectories and disease outcomes[3, 4]. It is appreciated that there are varied pathologies that may lead to physiological changes years before symptoms[5]; for example, hypopituitarism, Alzheimer's disease and other dementia, neuroendocrine dysfunction and psychological disorders[6-9]. There is a need to explore post-TBI physiology to identify at-risk patients of Alzheimer's disease.

Identifying and validating biomarkers that are significantly affected by TBI may be one way to reduce this gap[3]. Since the 1980s, biomarkers have been found to be valuable in health and medicine due to their cost effectiveness and measurability[3, 4]. However, current research focuses on TBI-specific biomarkers (like GFAP, S100B, NSE) that are not measured routinely because of the biomarkers' they stringent requirement for specialized assays, equipment, and trained professionals[10].

Generalized health biomarkers are used in routine health tests and provide insights about liver function, kidney function, lipid metabolism, glucose control, hormonal levels, and electrolyte balance[11]. Additionally, they are easily procured, and highly reproducible[11]. Various health biomarkers have an established relationship with TBI or, at least, with neurological health. As examples, vitamin D hormone (VDH), biologically active metabolite of vitamin D, has a protective role following TBI whereas its deficiency is hazardous[12]. IGF-1 may play a role in neuroprotective or neurorepair processes due to its upregulation on sites of TBI lesions[15]. Creatinine, potassium, sodium, and urea are associated with kidney function and essential for maintaining bodily homeostasis, and thus, may have a potential link to proper neurological health[16].

UK Biobank is a cohort of nearly 0.5 million UK participants that attended baseline assessment across 12 centers between 2006 and 2010. These participants have detailed physical information as well as electronic health record linkage (EHR). We conducted hypothesis-free analyses to explore differences in generalized health biomarkers for people post-TBI, relative to no TBI.

Word Count: 360 words

Methods

Participants

Data were obtained from the UK Biobank which is a general population cohort with 502,490 participants. The data was collected between 2006 and 2010 from people between the ages of 40 and 69 years (mean = 56.5; SD = 8.1), across 22 assessment centers across the UK. Only participants of white British ancestry were examined because there is evidence of phenotypic and genetic complexity according to ancestry, and UKB participants are predominantly white British.

Biomarkers

The UK Biobank collected data on 34 biomarkers (table 1).

The biomarker data was collected at the initial appointment (as baseline) from all 502,412 participants and from 20,000 patients present at the follow-up assessment in 2012-2013. Quality control was strictly undertaken for measurements, instrumentation, and analyses[17].

Oestradiol and rheumatoid factor (RF) were biomarkers with a relatively large number of values under measurable levels. Very low values were noted as 'missing' in the original data. However, if the participant reported significant values for a different biomarker, the oestradiol and/or RF value was recorded as the square root of the minimum agreed upon detectable value.

TBI Classification

TBI diagnoses were based on self-report at baseline, or ICD-10 codes prior to that date (i.e., historic TBI). TBI diagnoses were stratified into narrow-band and broad-band TBI to reduce bias as a result of broad-band TBI cases that are less likely to be true TBI cases.

Traumatic brain injury diagnoses were recorded via linkage to primary or secondary diagnoses records using ICD-10 codes for hospital inpatient admission[18]. The diagnosis was classified into broad-band TBI, which included 1,798 ICD- 10 codes related to head trauma, and narrow-band TBI, which was specific to TBI-related terminologies. Only TBI incidents prior to biomarker assessment were included. There was a total of 7,626 broad-band TBI cases, out of which 1,626 were narrow-band TBI cases.

Study Design

This is a prospective, cross-sectional, cohort study.

Participants with TBI diagnosis have been assessed against biomarkers separately across four models with incremental adjustment:

1) Model1 – unadjusted
2) Model2 – partially adjusted for sex, age, BMI, and assessment centers.
3) Model3 – intermediately adjusted for covariates from Model2, chronic neurological conditions (refer to table 2), and average sleep duration.
4) Model4 – fully adjusted for covariates included in Model2 and Model3, Townsend deprivation indices, smoking history, educational qualification, heart disease, type 2 diabetes, high blood pressure, medication, and duration of moderate physical activity.

Using progressive models systematically would distinguish the specific impact of a confounding factor. Also, presenting multiple models would help in communicating transparency in the objective behind analyses. A fully adjusted model would account for the complexity in real world relationships and readily apply to a diverse demographic.

Ethical Approval

Secondary data analysis is conducted using approval from the UK biobank ethics committee, NHS National Research Ethics Service and informed consent from all participants in the UK Biobank database for research, at the time of data collection.

Data availability statement

UK Biobank is an open access resource available to affiliated researchers (http://www.ukbiobank.ac.uk/). Analysis syntax is available from the authors upon request.

Covariates

Sex, age, weight, and height were measured during initial assessment visit. Assessment center refers to 1 of the 22 centers attended by participant. Educational qualification was self-reported and recorded as ‘1’ (at least university-level or college-level degree) or ‘0’. Duration of moderate physical activity was only accepted if response was between 0 and 1,440 minutes. Townsend deprivation indices were determined immediately prior to participation in the study based on postcode.

History of chronic neurological conditions (refer to table 2) was self-reported and included in the analyses as yes, i.e., history of at least 1 condition, vs. no. Sleep duration (in 24 hours) was self-reported. Smoking status was self-reported and collapsed into ‘never’ and ‘ever’, where ‘ever’ included both past and current smokers. Histories of heart disease, type 2 diabetes, and high blood pressure were self-reported and recorded individually. Self-report of medications was tabulated as yes vs. no.

Statistical Analyses

Multivariate linear regression analysis was done using R version 2022.12.0+353. Results were expressed as standardized betas, defined as difference in the outcome variable in standard deviation units (e.g., ß = 0.2 would correspond to 0.2 SDs higher than average for TBI history vs. no TBI history). These are used to provide information about the strength and direction of the relationship. Corresponding P-values and adjusted R^2 values were also calculated for each model across both strata.

Word Limit: 726 words

Results

The total number of participants, after exclusion, was 419,778; 7,626 are broad-band TBI, out of which 1,626 are narrow-band TBI. Distribution according to covariates can be found in tables 3 and 4.

Due to high missingness, average sleep duration and days between diagnosis and assessment were omitted from final analysis.

The results of the final analysis are reported in the form of standardized beta coefficients (ß), which are used to provide information about the strength and direction of the relationship between TBI history (independent variable) and the biomarker (dependent variable).

ß are presented through line plots in fig. 1 and fig. 2. The p-values heatmaps are intended to signify the analogous statistical significance (fig. 3 and fig. 4).


ized Beta Values for Each Biomarker and Model for narrow-band TBI
Calcium
Cholesterol
Creatinine
Creatinine (enzymatic)
CRP
Cystatin C
Direct Bilirubin
Gamma Glut.
Glucose
HbA1c
HDL
IGF-1
LDL
Lipoprotein (a)
Microalbumin
Oestradiol
Phosphate
Potassium
Protein
RF
SHBG
Sodium
Testosterone
Biomarker
Model1
Model2
Model3
Model4



The trends of statistical significance are evidenced in table 5, in which yellow boxes represent $P < 0.05$.

Aspartate aminotransferase, gamma glutamyltransferase, and IGF-1 are statistically significant across all models in narrow-band and broad-band TBI. Alkline phosphatase, apolipoprotein A (APOE A), calcium, C-reactive protein (CRP), cystatin C, and direct low-density lipoprotein (LDL) are found to be statistically significant across all models, except Model4 of narrow-band TBI. Enzymatic creatinine, glucose, HbA1c, and microalbumin are statistically significant in all Model1, Model2 and Model3 of both narrow-band and broad-band TBI.

Sex hormone-binding globulin (SHBG), albumin, oestradiol, and testosterone have significant results in all models of broad-band TBI; for narrow-band TBI, only Model1 and Model2 have significant results for SHBG, only Model2 and Model3 for albumin and only Model1 in oestradiol and testosterone. Creatinine has significant results only in in Model for broad-band TBI but across all models in in narrow-band TBI.

For cholesterol, Model1, Model2 and Model3 showed significang results in broad-band TBI and Model1 and Model2 in narrow-band TBI. Vitamin D shows significant results in Model1 in broad-band TBI and Model1 and Model2 in narrow-band TBI. Direct bilirubin, triglyceride, urate and sodium have significant results in Model1 in both broad-band and narrow-band TBI.

HDL and APOE A has significant results in Model2, Model3 and Model4 in broad-band TBI and Model1 in narrow-band TBI. Phosphate has significant results in Model2 and Model3 in broad-band and narrow-band TBI. Total bilirubin has significant results in Model2 and Model3 in broad-band TBI.

Alanine aminotransferase, urea, lipoprotein (a), RF, potassium and total protein have one significant result across all 8 models of the analysis which is Model1 in broad-band, Model 3 in broad-band, Model4 in broad-band, Model3 in broad-band, Model1 in narrow-band and Model1 in broad-band TBI, respectively.

Word Limit: 409 words

Discussion

This study aimed to investigate the association between generalized health biomarkers and a history of traumatic brain injury (TBI) using data from the UK Biobank. Large-scale studies examining systemic health biomarkers in TBI are scarce, and this study provides new insights into how such biomarkers relate to both broad-band and narrow-band TBI cases.

The analysis identified three key biomarkers—insulin-like growth factor-1 (IGF-1), gamma-glutamyltransferase (GGT), and aspartate aminotransferase (AST)—that remained significant across all models in both broad-band and narrow-band TBI groups. These biomarkers suggest robust links between TBI and systemic physiological processes such as growth factor regulation, oxidative stress, and hepatic function. Furthermore, six additional biomarkers (apolipoprotein B, alkaline phosphatase, calcium, C-reactive protein [CRP], cystatin C, and low-density lipoprotein [LDL]) were significant in various models, particularly within narrow-band TBI cases. Conversely, four biomarkers (enzymatic creatinine, glucose, HbA1c, and microalbumin) lost statistical significance in the fully adjusted models, suggesting confounding influences from additional covariates.

Interpretation of Significant Biomarkers

IGF-1 plays a fundamental role in neuroplasticity and neuronal repair. Previous research has demonstrated that IGF-1 is upregulated at sites of brain injury, promoting neuronal survival and synaptic plasticity[19]. Reduced serum IGF-1 levels in individuals with TBI may indicate impaired neuroprotective mechanisms, particularly in cases of chronic or repeated head trauma[20]. This aligns with animal studies where IGF-1 deficiency has been linked to hippocampal neuronal loss and cognitive decline post-TBI[21]. Additionally, low IGF-1 has been implicated in neurodegenerative diseases, further reinforcing its potential role in long-term TBI outcomes[22].

Gamma-glutamyltransferase (GGT) is an enzyme involved in glutathione metabolism and oxidative stress regulation. Elevated GGT levels in TBI patients suggest increased oxidative stress, which has been linked to both neuroinflammation and blood-brain barrier disruption[23]. Oxidative stress is known to exacerbate neurodegeneration post-TBI, further highlighting the relevance of this biomarker[24]. Aspartate aminotransferase (AST) is traditionally used as a liver function marker but is also present in the brain. Elevated AST levels in TBI patients may reflect neuronal cell damage, similar to what has been observed in ischemic stroke cases[25]. Studies suggest that AST release into circulation may serve as an indirect marker of neuronal injury severity[26].

Additional Biomarkers and Their Implications

Increased ALP levels were observed in TBI patients, a finding previously associated with neurodegenerative diseases and systemic inflammation[27]. While its direct role in TBI remains unclear, ALP may be linked to neuroinflammatory pathways. Lower APO B levels suggest disruptions in lipid transport, which may impact neurovascular health and cognitive function in TBI patients [28].Hypocalcemia was noted in TBI cases, consistent with previous findings associating low calcium levels with poor neurological recovery and increased intracranial pressure[29].Cystatin C, associated with kidney function and inflammation, was elevated in TBI patients. Higher cystatin C levels have been linked to neuroinflammatory conditions and cognitive impairment[30].Elevated CRP levels indicate a strong inflammatory response following TBI. Chronic inflammation post-TBI has been associated with increased risk of neurodegenerative diseases such as Alzheimer's and Parkinson's disease[31]. Decreased LDL levels in TBI patients suggest disruptions in cholesterol metabolism, potentially affecting myelin integrity and neuronal function[32].

Comparing Narrow-Band vs. Broad-Band TBI Results

This study found stronger biomarker associations in the broad-band TBI group, likely due to its larger sample size and broader inclusion criteria. However, the narrow-band TBI group, consisting of more clinically confirmed cases, provided more targeted insights into TBI severity. The distinction between these two classifications is crucial, as mild and moderate TBI cases often go undiagnosed in hospital settings, leading to underrepresentation in broad-band datasets[33]. Differences in biomarker expression between these groups may reflect injury severity, underlying comorbidities, or post-injury systemic changes[34].

Clinical Implications and Future Research

1. Potential for Biomarkers as Surrogate Endpoints

The findings suggest that generalized health biomarkers could serve as valuable surrogate markers for TBI prognosis. Given their routine use in clinical practice, these biomarkers could facilitate early identification of at-risk individuals and guide personalized intervention strategies. For instance, monitoring IGF-1 and GGT levels in TBI patients may provide insight into neuroinflammatory status and recovery trajectories[19].

2. Feasibility and Practical Applications

The accessibility of these biomarkers in routine health assessments underscores their potential for integration into clinical TBI management. Unlike specialized TBI-specific markers (e.g., GFAP, UCH-L1), which require advanced laboratory assays, the biomarkers identified in this study are widely measured in primary healthcare settings. This could enhance early diagnosis and long-term monitoring of TBI patients, particularly in resource-limited environments[35].

3. Need for Longitudinal Studies

Despite the strengths of this study, longitudinal research is necessary to establish causal relationships between these biomarkers and TBI progression. Future studies should investigate temporal changes in biomarker levels post-injury, exploring how fluctuations correlate with cognitive outcomes and rehabilitation efficacy. Additionally, the role of confounding factors, such as sleep disturbances and medication use, warrants further investigation[36].

Strengths and Limitations

This study uses a large sample size from the UK Biobank which enabled robust statistical analysis. This also allowed it to control for many demographic factors which could have confounding effects on the true relationship. External validity was preserved through stratification by TBI classification.

One of the biggest limitations of this study is the variability in biomarker collection methods which is further complicated by unreliability of non-fasting blood samples (which were used at various assessment centers). It is very poorly understood how biomarkers exit the nervous system to post-injury to enter the bloodstream[37].

This study only includes participants of white British background and from a relatively less deprived background[40]. This reduces the external validity of results. Due to high rates of missingness, this study could not control for days between self-reported TBI diagnoses and assessment for biomarkers which has potential of being a significant confounding factor since its physiological effect is time dependent. This is evidenced by multiple previously cited studies. Sleep disturbances have been widely observed post-TBI[38]. This may also be a crucial confounding factor that wasn't included in this study due to overwhelmingly large number of missing values.

Word Limit: 975 words

Conclusion

This study highlights the potential of generalized health biomarkers in understanding the systemic impact of TBI. The consistent associations observed for IGF-1, GGT, and AST suggest their role as key indicators of post-TBI physiological changes. While additional biomarkers exhibited significance in specific models, further validation is needed to explore their mechanistic underpinnings. The integration of these biomarkers into routine clinical practice could enhance diagnostic accuracy, improve patient monitoring, and facilitate early intervention strategies, ultimately contributing to better long-term outcomes for TBI patients.

Word Count: 82 words

References

1. Dewan, M. C., Rattani, A., Gupta, S., Baticulon, R. E., Hung, Y. C., Punchak, M., Agrawal, A., Adeleye, A. O., Shrime, M. G., Rubiano, A. M., Rosenfeld, J. V., & Park, K. B. (2018). Estimating the global incidence of traumatic brain injury. *Journal of Neurosurgery*, 130(4), 1080-1097. doi: 10.3171/2017.10.JNS17352.
2. Levin, H.S., Temkin, N.R., Barber, J., Nelson, L.D., Robertson, C., Brennan, J., Stein, M.B., Yue, J.K., Giacino, J.T., McCrea, M.A., Diaz-Arrastia, R., Mukherjee, P., Okonkwo, D.O., Boase, K., Markowitz, A.J., Bodien, Y., Taylor, S., Vassar, M.J., Manley, G.T. and Adeoye, O. (2021). Association of Sex and Age With Mild Traumatic Brain Injury–Related Symptoms: A TRACK-TBI Study. JAMA Network
3. Brody, D.L., Chan, L. and Cizza, G. (2019). How do you treat traumatic brain injury? One symptom at a time. Annals of Neurology, 86(3), pp.329–331.
4. National Academies of Sciences, E., Division, H. and M., Services, B. on H.C., Policy, B. on H.S., Care, C. on A.P. in T.B.I.R. and, Matney, C., Bowman, K. and Berwick, D. (2022). Gaps, Challenges, and Opportunities. [online]
5. Lyall, D.M., Russell, E., Ward, J. and Stewart, W.J. (2022). History of traumatic brain injury is associated with impaired cognition and imaging evidence of altered white matter tract integrity in UK Biobank (n=47,920). *PsyArXiv* (OSF Preprints). doi:https://doi.org/10.31234/osf.io/7wb9n.
6. Kałas, M., Miksiewicz, M., Kowalke, A., & Siemiński, M. (2023). Post-Traumatic Hypopituitarism: A Neglected Consequence of Traumatic Brain Injury. *Neuroendocrinology*, 113(6), 579–588. DOI: 10.1159/000529327
7. Ramos-Cejudo, J., Wisniewski, T., Marmar, C., Zetterberg, H., Blennow, K., de Leon, M.J. and Fossati, S. (2018). Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link. *EBioMedicine*, [online] 28, pp.21–30. doi:https://doi.org/10.1016/j.ebiom.2018.01.021.
8. West, T. and Sharp, S.R. (2014). Neuroendocrine dysfunction following mild TBI: when to screen for it. *PubMed*, 63(1), pp.11–6.
9. Gómez-de-Regil, L., Estrella-Castillo, D.F. and Vega-Cauich, J. (2019). Psychological Intervention in Traumatic Brain Injury Patients. *Behavioural Neurology*, [online] 2019, pp.1–8. doi:https://doi.org/10.1155/2019/6937832
10. Amoo, M., Henry, J., O'Halloran, P.J., Brennan, P., Husien, M.B., Campbell, M., Caird, J., Javadpour, M. and Curley, G.F. (2021). S100B, GFAP, UCH-L1 and NSE

as predictors of abnormalities on CT imaging following mild traumatic brain injury: a systematic review and meta-analysis of diagnostic test accuracy. Neurosurgical Review, 45(2), pp.1171–1193. doi:https://doi.org/10.1007/s10143-021-01678-z.

11. Califf, R.M. (2018). Biomarker Definitions and Their Applications. Experimental Biology and Medicine, 243(3), pp.213–221.
12. Lawrence, D.W. & Sharma, B. (2016) A review of the neuroprotective role of vitamin D in traumatic brain injury with implications for supplementation post-concussion. *Brain injury*, vol. 30, no. 8, pp. 960-968.
13. Yue, J.K., Xu, L., Korley, F., Puccio, A., Yuh, E., Sun, X., Rabinowitz, M., Vassar, M.J., Taylor, S., Winkler, E.A., Puffer, R., Deng, H., McCrea, M., Stein, M., Robertson, C.S., Levin, H., Dikmen, S., Temkin, N., Giacino, J.T., Mukherjee, P., Wang, K., Okonkwo, D.O., Markowitz, A., Jain, S., Manley, G.T. & Diaz-Arrastia, R. (2020). High-sensitivity C-Reactive Protein is a Prognostic Biomarker of 6-month Disability After Traumatic Brain Injury: Results from the TRACK-TBI Study. *Neurosurgery*, vol. 67, no. Supplement_1.
14. Dusick, J.R., Glenn, T.C., Vespa, P.M. & Martin, N.A. (2015). New Observations in Cerebral Glucose Metabolism Following Traumatic Brain Injury: The Mystery of the Missing Glucose 246 Studies in 74 Patients and Comparison to Normal Controls, *Neurosurgery*, vol. 62 Suppl 1, *CLINICAL NEUROSURGERY*, no. Supplement 1, pp. 200-200.
15. Mangiola, A., Vigo, V., Anile, C., De Bonis, P., Marziali, G. & Lofrese, G. (2015). Role and Importance of IGF-1 in Traumatic Brain Injuries, *BioMed research international*, vol. 2015, pp. 736104-12.
16. Ha, Y., Jeong, J.A., Kim, Y. & Churchill, D.G. (2016) Sodium and Potassium Relating to Parkinson's Disease and Traumatic Brain Injury, *Metal ions in life sciences*, vol. 16, pp. 585.
17. Fry, D., Almond, R., Moffat, S., Gordon, M. and Singh, P. (2019). UK Biobank Biomarker Project Companion Document to Accompany Serum Biomarker Data Prepared for: UK Biobank Showcase UK Biobank Biomarker Enhancement Project - Companion Document to Accompany Serum Biomarker Data. [online] Available at: https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/serum_biochemistry.pdf.
18. Lyall D, Russell E, Ward J, Stewart W. History of traumatic brain injury is associated with impaired cognition and imaging evidence of altered white matter tract integrity in UK Biobank (n=47,920). doi:10.31234/OSF.IO/7WB9N

19. Madathil, S. K., & Saatman, K. E. (2015). IGF-1/IGF-R signaling in traumatic brain injury: Impact on cell survival, neurogenesis, and behavioral outcome. *Neurochemical Research*, 40(12), 2449–2460. https://doi.org/10.1007/s11064-015-1743-2
20. Mangiola, A., Vigo, V., Anile, C., De Bonis, P., Marziali, G., Lofrese, G., & Pettorini, B. (2015). Role and importance of IGF-1 in traumatic brain injuries. BioMed Research International, 2015, 736104. https://doi.org/10.1155/2015/736104
21. Lichtenwalner, R. J., Forbes, M. E., Bennett, S. A., Lynch, C. D., Sonntag, W. E., & Riddle, D. R. (2001). Intracerebroventricular infusion of insulin-like growth factor-I ameliorates the age-related decline in hippocampal neurogenesis. Neuroscience, 107(4), 603–613. https://doi.org/10.1016/S0306-4522(01)00384-5
22. Sonntag, W. E., Ramsey, M., & Carter, C. S. (2005). Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging. Ageing Research Reviews, 4(2), 195–212. https://doi.org/10.1016/j.arr.2005.02.001
23. Lee, D. H., & Jacobs, D. R. (2009). Is serum gamma-glutamyltransferase a marker of oxidative stress? Free Radical Research, 43(6), 533–537. https://doi.org/10.1080/10715760902997312
24. Ansari, M. A., & Scheff, S. W. (2010). Oxidative stress in the progression of Alzheimer disease in the frontal cortex. Journal of Neuropathology & Experimental Neurology, 69(2), 155–167. https://doi.org/10.1097/NEN.0b013e3181cb5af4
25. Kim, H., & Lee, H. (2013). Serum liver enzyme levels and cerebral infarction: A prospective study in Korea. Stroke, 44(2), 304–310. https://doi.org/10.1161/STROKEAHA.112.675470
26. García-Bonilla, L., Campos, M., Giralt, D., Salat, D., Martínez-Saez, E., Hernández-Guillamon, M., & Montaner, J. (2012). Evidence for the efficacy of statins in animal stroke models: A meta-analysis. Journal of Neurochemistry, 122(2), 233–243. https://doi.org/10.1111/j.1471-4159.2012.07770.x
27. Kim, J. M., Stewart, R., Kim, S. Y., Kim, S. W., Yang, S. J., Shin, I. S., & Yoon, J. S. (2008). Changes in serum alkaline phosphatase and the risk of incident dementia over a 10-year period. Clinical Chemistry and Laboratory Medicine, 46(2), 218-223. https://doi.org/10.1515/CCLM.2008.038
28. Mahley, R. W., & Huang, Y. (2012). Apolipoprotein E sets the stage: Response to injury triggers neuropathology. Neuron, 76(5), 871–885. https://doi.org/10.1016/j.neuron.2012

29. Zemva, A., & Schaller, B. (2014). Hypocalcemia as a prognostic factor in mortality and morbidity in patients with moderate and severe traumatic brain injury. Journal of Neurosurgical Sciences, 58(1), 23–28.
30. Nair, A., Joseph, J., & Pillai, A. K. (2020). Higher cystatin C levels are associated with neurocognitive impairment in older adults. Journal of Geriatric Psychiatry and Neurology, 33(1), 3–10.
31. Sajja, V. S. S. S., & Hlavac, N. (2016). Blood biomarkers of traumatic brain injury: A review of recent research. Journal of Neurology and Neurophysiology, 7(3), 1–8.
32. Wright, W. G., & Reddy, C. C. (2014). Lipid metabolism in traumatic brain injury: Impact on prognosis and potential therapeutic targets. Journal of Neurotrauma, 31(12), 1008–1017.
33. Gardner, R. C., & Yaffe, K. (2015). Epidemiology of mild traumatic brain injury and neurodegenerative disease. Molecular and Cellular Neuroscience, 66, 75–80.
34. Yue, J. K., Upadhyayula, P. S., Avalos, L. N., Deng, H., & Winkler, E. A. (2020). Blood biomarkers for mild traumatic brain injury: A systematic review. Neurosurgical Focus, 49(4), E7.
35. Papa, L., & Robertson, C. S. (2016). Biomarkers in traumatic brain injury. Current Opinion in Critical Care, 22(2), 141–149.
36. Thelin, E. P., Zeiler, F. A., Ercole, A., Mondello, S., Büki, A., Bellander, B. M., Helmy, A., Menon, D. K., & Nelson, D. W. (2017). Serial sampling of serum protein biomarkers for monitoring human traumatic brain injury dynamics: A systematic review. Frontiers in Neurology, 8, 300.
37. Perry, C., Barrett, T., Yadav, A., Patel, V. and Hashim, M.A. (2019). P032 NONINVASIVE BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE MONITORING: DRAWBACKS AND POTENTIAL. Gastroenterology, 156(3), pp.S22–S23. doi:https://doi.org/10.1053/j.gastro.2019.01.083.
38. Larson, E.B. (2018). Sleep disturbance and cognition in people with TBI. *NeuroRehabilitation*, 43(3), pp.297–306. doi:https://doi.org/10.3233/nre-182534.
39. Olsson, T.M. and Sundell, K. (2023). Publication bias, time-lag bias, and place-of-publication bias in social intervention research: An exploratory study of 527 Swedish articles published between 1990–2019. *PLOS ONE*, 18(2), p.e0281110. doi:https://doi.org/10.1371/journal.pone.0281110.
40. Fry, A., Littlejohns, T. J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T., Collins, R., & Allen, N. E. (2017). Comparison of Sociodemographic and Health-Related

Characteristics of UK Biobank Participants With Those of the General Population. American journal of epidemiology, 186(9), 1026–1034. https://doi.org/10.1093/aje/kwx246

TABLE 1: Biomarkers

Biomarkers	Health Domain
Cholesterol	**Diabetes**
)irect Low Density Lipoprotein	**Renal**
HDL-Cholesterol	
Triglyceride	
Apolipoprotein A	
Apolipoprotein B	
C-reactive Protein	
Lipoprotein (a)	
Vitamin D	
Rheumatoid factor	
Alkaline Phosphatase	
Calcium	**Liver**
G (Sex Hormone-Binding Globulin)	
Testosterone	
Oestradiol	
-1 (Insulin-like Growth Factor 1)	
HbA1c	

Ga
A
As

TABLE 2: Neurological Conditions

malignant tumour	Meningitis
	Motor neurone
scess	Multiple scleros
	Neurological in
	Neuroma (benig
neurological problem	Other demyelin
's disease/cognitive impairment	Other neurologi
	Parkinson's dis
	Spina bifida
	Stroke
system	Subarachnoid h
	Subdural haema
alignant meningioma	Transient ischae
)	

TABLE 3: Summary of Descriptive Statistics				
Covariates	**No TBI History**	**TBI History**		**Missing Values**
		Broad-band	Narrow-band	
N	4,12,152	7,626	1,626	
Age (in years)	56.7 ± 7.98	57.06 ± 8.32	56.29 ± 8.27	
Sex				
Female	187,216 (45.42%)	3,901 (51.15%)	989 (60.82%)	
Male	224,936 (54.58%)	3,725 (48.85%)	637 (39.18%)	
Eduational qualification	128,052 (31.07%)	2014 (26.41%)	392 (24.11%)	3,480
BMI				1,765
<= 18.5	2,045	52	19	
> 18.5 and < 24.9	1,29,863	2,271	487	
>= 24.9	2,78,543	5,233	1,102	
History of chronic neurological condition	17,158 (4.16%)	882 (11.57%)	292 (17.96%)	16,532
Avg. sleep duration (in hours)	7.2	7.18	7.27	3,62,702
Smoking status				1,440
Never	225,143 (54.63%)	3,775 (49.5%)	753 (46.31%)	
Ever	185,601 (45.03%)	3,819 (50.07%)	863 (53.2%)	
History of heart disease	17,827 (4.33%)	614 (8.05%)	134 (8.24%)	666
History of type 2 diabetes	19,050 (4.62%)	546 (7.16%)	127 (7.81%)	928
History of high blood pressure	108,937 (26.43%)	2,398 (31.45%)	525 (32.29%)	666
Medication	10,190 (2.47%)	97 (1.27%)	18 (1.11%)	116
Avg. moderate physical activity time (in min)	66.7	73.54	76.94	1,09,662
Avg. days b/w TBI diagnosis and assessment	N/A	2,011	2,100	4,12,152
Avg. townsend deprivation	-1.57 ± 2.92	-0.71 ± 3.43	-0.29 ± 3.61	507
				TOTAL = 419,778

TABLE 4: Frequency by Assessment Centre (in %)			
Centre Code	**No TBI History**	**Broad-band TBI**	**Narrow-band TBI**
10003	0.73	0.50	0.18
11001	2.63	2.02	2.40
11002	2.82	1.60	1.72
11003	3.67	7.03	2.28
11004	3.47	9.39	5.10
11005	3.36	9.31	3.14
11006	4.23	2.45	2.83
11007	6.02	3.21	4.00
11008	5.82	5.61	6.70
11009	8.01	7.02	6.89
11010	9.25	6.57	9.41
11011	9.11	6.91	8.36
11012	1.75	1.61	2.64
11013	7.13	5.57	6.70
11014	6.57	5.66	8.49
11016	6.77	8.81	10.76
11017	4.66	3.71	4.31
11018	4.38	3.32	3.75
11020	4.37	3.57	4.37
11021	4.64	4.16	5.35
11022	0.46	1.63	0.37
11023	0.14	0.34	0.25

P-Values for narrow-band TBI

Model1	Model2	Model3	Model4
0.005	0.021	0.075	0.
0.750	0.118	0.049	0.
<0.001	0.343	0.977	0.
0.004	0.740	0.531	0.
0.125	0.176	0.343	0.
<0.001	0.253	0.132	0.
<0.001	0.290	0.407	0.
0.003	0.020	0.091	0.
0.473	0.314	0.180	0.
0.598	0.374	0.557	0.
0.038	0.548	0.811	0.
0.891	0.018	0.045	0.
0.028	0.654	0.878	0.
<0.001	<0.001	0.003	0.
0.302	0.223	0.162	0.
<0.001	<0.001	0.020	0.
<0.001	<0.001	<0.001	<0
<0.001	0.044	0.027	0.
<0.001	<0.001	<0.001	0.
<0.001	<0.001	0.016	0.
<0.001	<0.001	<0.001	<0
<0.001	0.226	0.350	0.
<0.001	<0.001	<0.001	0.
<0.001	<0.001	<0.001	0.
<0.001	0.017	0.046	0.
<0.001	0.037	0.001	0.
<0.001	0.004	0.224	0.
<0.001	0.007	0.039	0.
<0.001	0.001	<0.001	0.
<0.001	<0.001	0.011	0.
<0.001	0.128	0.084	0.
0.001	<0.001	0.005	0.
0.130	0.006	0.023	0.
0.054	0.153	0.337	0.

Model

P-Values for broad-band TBI

Model1	Model2	Model3	Model4
<0.001	0.074	0.165	0.
0.122	0.605	0.442	0.
<0.001	0.268	0.100	0.
0.018	0.650	0.734	0.
0.247	0.002	0.014	0.
<0.001	0.002	<0.001	0.
<0.001	0.511	0.374	0.
0.044	<0.001	<0.001	<0
0.175	0.126	0.048	0.
0.036	0.204	0.653	0.
0.141	0.989	0.785	0.
0.102	0.003	0.003	0.
<0.001	0.041	0.019	0.
<0.001	0.001	0.005	0.
0.050	0.070	0.066	0.
<0.001	<0.001	<0.001	0.
<0.001	<0.001	<0.001	<0
0.147	<0.001	<0.001	<0
<0.001	<0.001	<0.001	0.
<0.001	<0.001	<0.001	0.
<0.001	<0.001	<0.001	<0
<0.001	0.061	0.072	0.
<0.001	<0.001	<0.001	<0
<0.001	<0.001	<0.001	0.
<0.001	0.007	0.032	0.
<0.001	0.612	0.633	0.
<0.001	<0.001	<0.001	0.
<0.001	<0.001	0.005	0.
<0.001	<0.001	<0.001	<0
<0.001	<0.001	<0.001	0.
0.088	<0.001	<0.001	<0
<0.001	<0.001	<0.001	<0
<0.001	<0.001	<0.001	0.
<0.001	0.977	0.981	0.

Model

Table 5: Significance in Biomarkers

		Broad-band Analysis				Narrow-band Analysis				
S.No.	Biomarker	Model1	Model2	Model3	Model4	Model1	Model2	Model3	Model4	Health Domain
1	Aspartate									Liver
2	Gamma Glut.									Liver
3	IGF-1									Cancer
4	Alkaline Phosphatase									Bone and joint
5	APOE B									Cardiovascular
6	Calcium									Bone and joint
7	CRP									Cardiovascular
8	Cystatin C									Renal
9	LDL									Cardiovascular
10	Creatinine (enzymatic)									Renal
11	Glucose									Diabetes
12	HbA1c									Diabetes
13	Microalbumin									Renal
14	SHBG									Cancer
15	Albumin									Liver
16	Oestradiol									Cancer
17	Testosterone									Cancer
18	Creatinine									Renal
19	Cholesterol									Cardiovascular
20	Vitamin D									Bone and joint
21	Direct Bilirubin									Liver
22	Triglyceride									Cardiovascular
23	Urate									Renal
24	Sodium									Renal
25	HDL									Cardiovascular
26	APOE A									Cardiovascular
27	Phosphate									Bone and joint
28	Total Bilirubin									Liver
29	Alanine									Liver
30	Urea									Renal
31	Lipoprotein (a)									Cardiovascular
32	RF									Bone and joint
33	Potassium									Renal
34	Protein									Renal

Fig 1. Standardized Beta Values for Each Biomarker and Model for narrow-band TBI



Fig 2. Standardized Beta Values for Each Biomarker and Model for broad-band TBI



Fig 3. P-Values for narrow-band TBI

Biomarker	Model1	Model2	Model3	Model4
Vitamin D	0.005	0.021	0.075	0.479
Urea	0.750	0.118	0.049	0.057
Urate	<0.001	0.343	0.877	0.455
Triglyceride	0.004	0.740	0.531	0.897
Total Bilirubin	0.125	0.176	0.343	0.766
Testosterone	<0.001	0.253	0.132	0.147
Sodium	<0.001	0.290	0.407	0.962
SHBG	0.003	0.020	0.091	0.248
RF	0.473	0.314	0.180	0.771
Protein	0.598	0.374	0.557	0.402
Potassium	0.038	0.548	0.811	0.992
Phosphate	0.801	0.018	0.045	0.476
Oestradiol	0.028	0.654	0.678	0.867
Microalbumin	<0.001	<0.001	0.003	0.978
Lipoprotein (a)	0.302	0.223	0.162	0.281
LDL	<0.001	<0.001	0.020	0.914
IGF-1	<0.001	<0.001	<0.001	<0.001
HDL	<0.001	0.044	0.027	0.004
HbA1c	<0.001	<0.001	<0.001	0.198
Glucose	<0.001	<0.001	0.016	0.378
Gamma Glut.	<0.001	<0.001	<0.001	<0.001
Direct Bilirubin	<0.001	0.226	0.350	0.469
Cystatin C	<0.001	<0.001	<0.001	0.319
CRP	<0.001	<0.001	<0.001	0.342
Creatinine (enzymatic)	<0.001	0.017	0.046	0.669
Creatinine	<0.001	0.037	0.001	0.004
Cholesterol	<0.001	0.004	0.224	0.376
Calcium	<0.001	0.007	0.039	0.151
Aspartate	<0.001	0.001	<0.001	0.014
APOE B	<0.001	<0.001	0.011	0.675
APOE A	<0.001	0.128	0.084	0.054
Alkaline Phosphatase	0.001	<0.001	0.005	0.592
Albumin	0.130	0.006	0.023	0.363
Alanine	0.054	0.153	0.337	0.478

Model

P-Values

Fig 4. P-Values for broad-band TBI